1-3 of 3
Erwin R. Boghaert
Close
Sort by
Journal Articles

Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models

Deepak Sampath, PhD, Elizabeth Punnoose, PhD, Erwin R. Boghaert, PhD, Lisa Belmont, PhD, Jun Chen, PhD, Franklin Peale, MD, PhD, Nguyen Tan, Walter Darbonne, Peng Yue, PhD, Jason Oeh, Leslie Lee, Wayne J. Fairbrother, PhD, Andrew J. Souers, PhD, Steve W. Elmore, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2012) 120 (21): 5028.
https://doi.org/10.1182/blood.V120.21.5028.5028
Published: 2012
Journal Articles

Antibody-Targeted Chemotherapy with Immunoconjugates of Calicheamicin: Differential Anti-Tumor Activity of Conjugated Calicheamicin Targeted to B-Cell Lymphoma Via B-Cell Lineage Specific Molecules CD19, CD20 and CD22.

John F. DiJoseph, Douglas C. Armellino, Maureen M. Dougher, Arthur Kunz, Erwin R. Boghaert, Philip R. Hamann, Karen Zinkewich-Peotti, Nitin K. Damle
Journal: Blood
Blood (2004) 104 (11): 2490.
https://doi.org/10.1182/blood.V104.11.2490.2490
Published: 2004
Journal Articles

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas C. Armellino, Erwin R. Boghaert, Kiran Khandke, Maureen M. Dougher, Latha Sridharan, Arthur Kunz, Philip R. Hamann, Boris Gorovits, Chandrasekhar Udata, Justin K. Moran, Andrew G. Popplewell, Sue Stephens, Philip Frost, Nitin K. Damle
Journal: Blood
Blood (2004) 103 (5): 1807–1814.
https://doi.org/10.1182/blood-2003-07-2466
Published: 2004